Portfolio Update and Presentation
EMV Capital plc will host a virtual investor event on July 27, 2026, to provide updates on its portfolio companies AMR Bio and ProAxsis. AMR Bio will share progress on its XF-73 asset as it moves towards Phase 3 trials, while ProAxsis will discuss its repositioning and growth in the COPD market, including a clinical study with Imperial College London. The event aims to offer investors deeper insights into these deep tech and life sciences ventures, with questions able to be submitted in advance or during the live presentation.
Select text to share a quote on X · sign in to keep highlights & notes in your EMVC notes
Portfolio Update
As part of its ongoing investor engagement programme, EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that it will host a virtual Meet the Portfolio event on 27 July 2026 at 2.00 p.m. The session will provide investors with greater insight into two of its portfolio companies, AMR Bio and ProAxsis.
Virtual Meet the Portfolio - AMR Bio and ProAxsis
The online event will take place via the Investor Meet Company platform and will be hosted by Dr Ilian Iliev, CEO of EMV Capital plc, who will be joined by:
- Nigel Brooksby, Executive Chair of AMR Bio, a clinical phase biotechnology company dedicated to infection prevention, who will provide an update on the progress of its XF-73 asset as it advances towards Phase 3 clinical trials, and
- Dr Louise Ryan Murphy, Managing Director of ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights, who will provide an update on the Company's repositioning and recent progress, including its growth in the COPD market through a clinical study with Imperial College London.
This presentation is open to all interested parties. Anyone can sign up for free and join the live presentation via:
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 26 July 2026 at 9:00 a.m., or at any time during the live presentation.
In accordance with UK Market Abuse Regulation (UK MAR), no inside information will be disclosed during the event.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.